Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19171338 | 0.87 | NPC1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL3514860 | 0.86 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL20017302 | 0.85 | NPC1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19171376 | 0.83 | EPHX1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19164342 | 0.83 | NPC1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19171900 | 0.81 | EPHX1 (0.60) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL19171947 | 0.81 | EPHX1 (0.60) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL3512598 | 0.81 | NPC1 (0.52) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL7816137 | 0.81 | KDM4C (0.67) | NPC1RAB9AMAPTSMN1; SMN2KDM4C | |
| SCHEMBL15341360 | 0.80 | NPC1 (0.46) | NPC1RAB9AMAPTSMN1; SMN2KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2021-02-18 | — | — | US | disclosed |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | ASTRAZENECA AB (SE) | 2020-12-08 | — | — | US | disclosed |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | ASTRAZENECA AB (SE) | 2020-09-24 | — | — | US | disclosed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047312-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PIK3CD, PIK3CG, PIK3CA | NPC1 1960/4885RAB9A 605/4885MAPT 3876/4885 |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | NPC1 1148/4885RAB9A 1851/4885MAPT 4503/4885 |
| US-10858355-B2 | Inhibitors of phosphatidylinositol 3-kinase gamma | PIK3CD, PIK3CG, PIK3CA | NPC1 1960/4885RAB9A 605/4885MAPT 3876/4885 |
| US-20200299289-A1 | NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA | PI4KA, PIK3CD, PI4KB | NPC1 1903/4885RAB9A 609/4885MAPT 3099/4885 |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | NPC1 398/4885RAB9A 2638/4885MAPT 4479/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | NPC1 3555/4885RAB9A 692/4885MAPT 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.